Manufacturer of Brigatinib/Brigatinib

Brigatinib/Brigatinib, sold under the brand name Alunbig and other brands, is a small molecule targeted cancer therapy developed by Ariad Pharmaceuticals, Inc. and subsequently acquired by Takeda Pharmaceutical Co., Ltd. in February 2017. Brigatinib acts as an inhibitor of both anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). If brigatinib is combined with an anti-EGFR antibody such as cetuximab or panitumumab, it can overcome the resistance to osimertinib conferred by the EGFR C797S mutation.

Treatment guidelines for patients with stage IV non-small cell lung cancer with altered ALK drivers generally support the use of brigatinib as an option in the first- and second-line settings following crizotinib therapy. Epidermal growth factor receptor (EGFR) is another effective target in non-small cell lung cancer. In addition, the T790M “gatekeeper” mutation is associated with approximately 50% of patients who develop resistance to first-generation EGFR inhibitors. Although second-generation EGFR inhibitors are in development, clinical efficacy is limited due to toxicities thought to be associated with inhibition of native (endogenous or non-endogenous) EGFR.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).